International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 3, Issue 9 | Short Communication | Open Access DOI
Nemat Khansari*
Department of Immunology, Tehran University of Medical Sciences, School of Medicine, Iran
*Correspondence to: Nemat Khansari
Fulltext PDFCancer immunotherapy has seen significant advancements, offering more effective and personalized treatments. Emerging technologies, such as artificial intelligence and engineering approaches, have enabled the development of immunotherapies that precisely target individual tumor characteristics, empowering the immune system to combat the disease. This approach is based on the understanding that cancer is not a monolithic disease but encompasses a diverse array of genetic and phenotypic variations. The integration of immunotherapy with targeted therapies has shown promise in improving patient outcomes, particularly in cases where conventional treatments have failed or are less effective. When appropriately targeted, tumor-associated antigens (TAAs)or neoantigens unique to an individual's cancer can elicit a robust immune response. Advances in genomic sequencing technologies have facilitated the identification of these neoantigens, leading to the development of personalized cancer vaccines designed to stimulate the immune system against these unique targets.
Nemat Khansari. The Vital Role of Personalized Target Cancer Immunotherapy. Int Clinc Med Case Rep Jour. 2024;3(9):1-6.